Machine learning is the new big data. Combine the two fields, and you really have something.
Boston-area startup DataRobot has raised a $33 million Series B round, led by New Enterprise Associates. Other participating investors included Accomplice, Intel Capital, and... Read more »
Diffbot, an artificial intelligence company that helps clients extract and combine data from multiple Web sources, announced today it raised $10 million from investors including Tencent and Felicis Ventures to expand its “knowledge-as-a-service” offerings to businesses and consumer apps.
The... Read more »
San Antonio — For 11 early stage businesses in San Antonio, TX, three months of planning, trepidation, and retooling business plans is coming to a head. The participants of the Techstars Cloud accelerator program are holding their Demo Day today in... Read more »
BrightStar Wisconsin Foundation has made its first investment of 2016 and has sold $500,000 in “early-stage seed” tax credits to several individuals, the foundation said this week.
Phoenix Nuclear Labs, a Madison, WI-based startup that has developed particle accelerator technology with... Read more »
[Updated 2/11/16, 10:52 a.m., to include the DataCamp announcement.] This week, we’re tracking the latest news about DraftKings, Disney’s local research lab, startup funding announcements, and layoffs at tech companies. Read on for details.
—Disney is closing its Cambridge,... Read more »
Will ExoSOLS give a maker of 3D-printed foot care products a boost in scaling up?
On Thursday, New York-based SOLS introduced a new app, revised website, and ExoSOLS, the chief product in its new “science of comfort” line.
When we first... Read more »
Biotech and pharma executives from across the country descended on frigid midtown Manhattan this week for the BIO CEO & Investor Conference, and we’ve got a few tidbits from the festivities—as well as the rest of your East Coast headlines—below. But... Read more »
The stock markets haven’t been kind to biotech companies this year whether the companies are already public or trying to be. Proteostasis Therapeutics, a developer of drugs for cystic fibrosis and other diseases, is the latest example. It had to significantly... Read more »
TRImaran Pharma aims to take on a group of neurological diseases, like depression, by developing drugs that impact three different types of neurotransmitters in the brain. Those drug prospects come from Wayne State University, which licensed a group of molecules to... Read more »